Neil Parkin
Research areas: Medicine · Infectious Diseases · HIV/AIDS drug development and treatment · HIV Research and Treatment · HIV/AIDS Research and Interventions
0000-0001-5824-3388
About
Neil T. Parkin, Ph.D., is a scientific consultant with extensive experience in the area of viral drug resistance and molecular diagnostics, especially HIV and HCV. In November 2009, he founded Data First Consulting, Inc., currently based in Sebastopol, CA.
From July 2008 to October 2009, Dr. Parkin worked at the World Health Organization in Geneva, Switzerland, in the HIV/AIDS department as part of the HIV Drug Resistance team assisting laboratories around the world to perform high quality resistance testing for public health monitoring purposes.
Prior to working at WHO, Dr. Parkin was Senior Scientific Director at Monogram Biosciences (formerly ViroLogic Inc., now owned by LabCorp) in South San Francisco, California, for 11 years, and participated in the initial development of the PhenoSense HIV drug susceptibility test. He led research on HIV-1 and HCV drug resistance to develop new resistance assays, and to better understand the relationship between phenotype, genotype and viral replication.
From 1993 to 1996, Dr. Parkin was a Scientist at Aviron, Inc., where he was responsible for the development of an engineered live attenuated influenza A virus vaccine and for overseeing transition of candidate vaccine strains from discovery through preclinical testing.
Dr. Parkin received his PhD degree in biochemistry from McGill University in Montréal, Canada. He completed his postdoctoral training in the laboratory of Dr. Harold Varmus at the University of California, San Francisco.
The primary or coauthor of over 100 articles in virology, oncology, infectious disease, and genetics, Dr. Parkin also holds multiple patents relating to his work in HIV and influenza. See https://www.ncbi.nlm.nih.gov/myncbi/1d5rXWSKyfD56/bibliography/public/
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (12)
- Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios Save
- Evaluation of Blood Droplet Volumes on the Cobas Plasma Separation Card for HCV RNA Testing in Resource‐Limited Settings Save
- Dried Blood Spots and Plasma Separation Cards can Broaden Access to Molecular Testing for HBV, HCV and HIV Save
- Context‐dependent accuracy of the cobas plasma separation card for HCV RNA viral load measurement Save
- Need assessment for HIV drug resistance testing and landscape of current and future technologies in low- and middle-income countries Save
- Application of a Sanger-Based External Quality Assurance Strategy for the Transition of HIV-1 Drug Resistance Assays to Next Generation Sequencing Save
- Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds Save
- Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping Save
- Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations Save
- Are We Ready for NGS HIV Drug Resistance Testing? The Second “Winnipeg Consensus” Symposium Save
- External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations Save
- Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons Between Candidate Anti-Coronavirus Compounds Save